Market Closed -
Nasdaq
01:30:00 02/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.09
USD
|
+3.81%
|
|
-3.11%
|
-24.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
358.7
|
591.4
|
453.2
|
259.3
|
252.8
|
184.1
|
-
|
-
|
Enterprise Value (EV)
1 |
358.7
|
591.4
|
453.2
|
259.3
|
252.8
|
184.1
|
184.1
|
184.1
|
P/E ratio
|
-5.35
x
|
-19.4
x
|
-24.1
x
|
-4.41
x
|
-10.4
x
|
-12.4
x
|
12.7
x
|
4.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.05
x
|
5.44
x
|
3.04
x
|
2.16
x
|
2.16
x
|
1.23
x
|
0.96
x
|
0.81
x
|
EV / Revenue
|
6.05
x
|
5.44
x
|
3.04
x
|
2.16
x
|
2.16
x
|
1.23
x
|
0.96
x
|
0.81
x
|
EV / EBITDA
|
-
|
-20.9
x
|
-58
x
|
-4.87
x
|
-13.1
x
|
-13
x
|
8.61
x
|
3.26
x
|
EV / FCF
|
-8.35
x
|
-
|
-
|
-
|
-
|
-
|
6.14
x
|
3.35
x
|
FCF Yield
|
-12%
|
-
|
-
|
-
|
-
|
-
|
16.3%
|
29.9%
|
Price to Book
|
2.58
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,67,611
|
1,68,981
|
1,71,006
|
1,72,836
|
1,74,370
|
1,75,378
|
-
|
-
|
Reference price
2 |
2.140
|
3.500
|
2.650
|
1.500
|
1.450
|
1.090
|
1.090
|
1.090
|
Announcement Date
|
27/02/20
|
02/03/21
|
01/03/22
|
07/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
59.29
|
108.6
|
149.2
|
120.2
|
116.9
|
149.5
|
192.2
|
227.9
|
EBITDA
1 |
-
|
-28.27
|
-7.813
|
-53.23
|
-19.25
|
-14.16
|
21.39
|
56.47
|
EBIT
1 |
-69.09
|
-28.97
|
-12.5
|
-55.55
|
-20.49
|
-11.74
|
21.78
|
49.64
|
Operating Margin
|
-116.53%
|
-26.67%
|
-8.37%
|
-46.2%
|
-17.53%
|
-7.85%
|
11.33%
|
21.78%
|
Earnings before Tax (EBT)
1 |
-66.89
|
-29.74
|
-17.31
|
-58.57
|
-25.09
|
-16.2
|
18.08
|
48.66
|
Net income
1 |
-66.89
|
-29.74
|
-17.91
|
-58.57
|
-25.09
|
-16.2
|
18.08
|
48.35
|
Net margin
|
-112.83%
|
-27.38%
|
-12%
|
-48.71%
|
-21.47%
|
-10.84%
|
9.41%
|
21.21%
|
EPS
2 |
-0.4000
|
-0.1800
|
-0.1100
|
-0.3400
|
-0.1400
|
-0.0876
|
0.0855
|
0.2351
|
Free Cash Flow
1 |
-42.96
|
-
|
-
|
-
|
-
|
-
|
30
|
55
|
FCF margin
|
-72.47%
|
-
|
-
|
-
|
-
|
-
|
15.61%
|
24.13%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
140.27%
|
97.39%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
165.91%
|
113.76%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
02/03/21
|
01/03/22
|
07/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
21.54
|
20.41
|
16.74
|
29.82
|
46.55
|
22.41
|
51.28
|
26.07
|
26.89
|
28.13
|
35.79
|
31.47
|
33.44
|
38.04
|
42.03
|
41.32
|
EBITDA
1 |
-19.52
|
-17.49
|
-26.02
|
-
|
-
|
-18.16
|
-
|
-12.37
|
-4.971
|
-4.173
|
2.259
|
-3.861
|
-3.756
|
-7.581
|
1.036
|
-
|
EBIT
1 |
-19.78
|
-21.42
|
-26.26
|
-12.96
|
-
|
-18.4
|
2.079
|
-12.72
|
-5.267
|
-4.465
|
1.966
|
-3.484
|
-2.549
|
-8.51
|
3.439
|
-0.66
|
Operating Margin
|
-91.84%
|
-104.94%
|
-156.92%
|
-43.48%
|
-
|
-82.12%
|
4.05%
|
-48.81%
|
-19.59%
|
-15.87%
|
5.49%
|
-11.07%
|
-7.62%
|
-22.37%
|
8.18%
|
-1.6%
|
Earnings before Tax (EBT)
1 |
-21.09
|
-22.7
|
-27.44
|
-13.49
|
-
|
-19.04
|
1.401
|
-13.54
|
-6.6
|
-5.692
|
0.737
|
-4.678
|
-3.998
|
-8.779
|
1.257
|
-1.103
|
Net income
1 |
-20.95
|
-22.64
|
-27.44
|
-13.49
|
-
|
-19.04
|
1.401
|
-13.54
|
-6.6
|
-5.692
|
0.737
|
-4.678
|
-3.998
|
-8.779
|
1.257
|
-1.103
|
Net margin
|
-97.26%
|
-110.94%
|
-164%
|
-45.25%
|
-
|
-84.95%
|
2.73%
|
-51.92%
|
-24.55%
|
-20.23%
|
2.06%
|
-14.86%
|
-11.96%
|
-23.08%
|
2.99%
|
-2.67%
|
EPS
2 |
-0.1200
|
-0.1300
|
-0.1600
|
-0.0800
|
-
|
-0.1100
|
0.0100
|
-0.0800
|
-0.0400
|
-0.0300
|
-
|
-0.0288
|
-0.0214
|
-0.0515
|
0.007550
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/11/21
|
01/03/22
|
03/05/22
|
02/08/22
|
02/08/22
|
03/11/22
|
07/03/23
|
02/05/23
|
01/08/23
|
07/11/23
|
05/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43
|
-
|
-
|
-
|
-
|
-
|
30
|
55
|
ROE (net income / shareholders' equity)
|
-53.7%
|
-
|
-55.6%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-46.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
143.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.8300
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.46
|
-
|
0.63
|
0.45
|
-
|
-
|
-
|
-
|
Capex / Sales
|
2.45%
|
-
|
0.42%
|
0.37%
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
02/03/21
|
01/03/22
|
07/03/23
|
05/03/24
|
-
|
-
|
-
|
Last Close Price
1.09
USD Average target price
4.567
USD Spread / Average Target +318.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.83% | 184M | | -1.17% | 102B | | +2.87% | 96.09B | | +2.13% | 22.28B | | -14.77% | 21.4B | | -8.79% | 18.14B | | -39.98% | 17.02B | | -13.21% | 16.09B | | +8.55% | 13.83B | | +35.75% | 11.97B |
Bio Therapeutic Drugs
|